Diabetes Is an Independent Predictor for Severe Osteoarthritis

Results from a longitudinal cohort study

OBJECTIVE—To evaluate if type 2 diabetes is an independent risk predictor for severe osteoarthritis (OA).

RESEARCH DESIGN AND METHODS—Population-based cohort study with an age- and sex-stratified random sample of 927 men and women aged 40–80 years and followed over 20 years (1990–2010).

RESULTS—Rates of arthroplasty (95% CI) were 17.7 (9.4–30.2) per 1,000 person-years in patients with type 2 diabetes and 5.3 (4.1–6.6) per 1,000 person-years in those without (P < 0.001). Type 2 diabetes emerged as an independent risk predictor for arthroplasty: hazard ratios (95% CI), 3.8 (2.1–6.6) in an unadjusted analysis and 2.1 (1.1–3.8) (P = 0.023) after adjustment for age, BMI, and other risk factors for OA. The probability of arthroplasty increased with disease duration of type 2 diabetes and applied to men and women, as well as subgroups according to age and BMI. Our findings were corroborated in cross-sectional evaluation by more severe clinical symptoms of OA and structural joint changes in subjects with type 2 diabetes compared with those without type 2 diabetes.

CONCLUSIONS—Type 2 diabetes predicts the development of severe OA independent of age and BMI. Our findings strengthen the concept of a strong metabolic component in the pathogenesis of OA.

Osteoarthritis (OA) is among the most frequent chronic diseases in the industrialized world, with estimation for the lifetime prevalence ranging from 30–50% (1,2). Moreover, OA is associated with a substantial disease burden due to pain, functional decline and increased mortality (2). In a proportion of individuals, OA progresses toward joint failure requiring total joint replacement (arthroplasty). In the U.S., 200,000 hip joints are replaced every year, and intervention rates for hip and knee OA are between 50 to 130 per 100,000 person-years in most Western countries (3). Relevance of OA for public health will further increase owing to the incremental ageing and overnutrition (4). OA already constitutes a major source of morbidity and is considered as driving force of health costs in aged populations next to cardiovascular disease, type 2 diabetes, and dementia. Despite the striking impact of OA, its etiopathogenesis is still poorly defined, with limited experimental insights into disease mechanisms and the underlying risk factors. It is well established, however, that OA shares similarities with type 2 diabetes, including its chronic nature, high prevalence of end-organ failure, and strong association with age and obesity (5–7). Whether type 2 diabetes represents a causal risk factor for OA remains unclear to date (8). Metabolic factors are important for the development of OA as suggested by several lines of evidence: 1) The association between obesity and OA extends beyond weight-bearing joints, suggesting that this link is not solely based on mechanical factors (9). 2) Metabolic syndrome is significantly more common among subjects with than without OA (10,11). In accordance, fasting glucose levels are higher in OA patients than in non-OA controls (11,12). 3) Finally, a small cross-sectional study from the 1960s (13) showed higher prevalence of radiographic OA in diabetic subjects than in nondiabetic individuals and a later evaluation on radiographic hip OA in patients receiving hip arthroplasty showed a surplus of bilateral joint involvement in diabetic patients (13,14).

In this study, we hypothesize that type 2 diabetes indeed represents an independent risk factor for the development of severe OA. We thus investigated the risk for arthroplasty, as well as clinical symptoms and imaging signs of OA in diabetic and nondiabetic subjects included in the long-term population-based Bruneck Study.

From the 1Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany; the 2Department of Rheumatology, Sapienza University of Rome, Rome, Italy; the 3Department of Radiology, University of Innsbruck, Innsbruck, Austria. Corresponding authors: Georg Schett, georg.schett@uk-erlangen.de, and Stefan Kiechl, stefan.kiechl@i-med.ac.at.

Received 12 May 2012 and accepted 24 July 2012.

DOI: 10.2337/dc12-0924

© 2013 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
access to one public health care system, represented by the Bruneck Hospital, which is the only health care provider in the entire region. Thus, all medical records of each individual were collected and completely accessible in the same place, minimizing bias due to incomplete medical information.

Patients
The study population was recruited in 1990 (baseline) as a random sample ($n = 1,000$), stratified according to sex and age, of all inhabitants of Bruneck (125 women and 125 men in each of the fifth to eighth decades of age). A total of 927 men and women were enrolled and followed until 2010, with examinations conducted every 5 years (1990, 1995, 2000, 2005, and 2010) and participation rates >90%. Population mobility within the Bruneck area was low at 0.2% per year and migration to outside communities was a rare event ($n = 4$ during the 20 years of follow-up). We succeeded to trace all of these few individuals, who participated in the follow-up exam or provided access to their medical records.

Data on type 2 diabetes and arthroplasty were available in all 927 subjects, including 576 subjects who were alive in 2010 and 351 subjects who died during the 20 years of follow-up. The study protocol of the Bruneck Study was reviewed and approved by the ethics committees of Bolzano and Verona, and all study subjects gave their written informed consent.

Baseline and follow-up examinations
At baseline and each 5-year follow-up, demographic and socioeconomic characteristics, comorbidities, and medication (including antidiabetic treatment, analgesic, and nonsteroidal anti-inflammatory drugs) were recorded. Assessment of comorbidities included cardiovascular disease (angina, myocardial infarction, heart failure, claudication, and stroke), cancer, chronic obstructive pulmonary disease (including asthma, bronchitis, and emphysema), arterial hypertension, chronic inflammatory disease, and neuropsychiatric disorders. Data were retrieved from 1) clinical history taking and medical record review; 2) complete physical and neurologic examination; and 3) measures such as blood pressure recording, electrocardiography, and carotid ultrasonography. Polyneuropathy was ascertained by a thorough clinical examination conducted by an experienced senior neurologist and graded as mild (sub- or preclinical disease), moderate (manifest sensory and/or motor deficits), or severe (disabling disease with severe impairment of gait).

Ascertainment of type 2 diabetes
Presence of type 2 diabetes was diagnosed according to the classic American Diabetes Association criteria (fasting glucose ≥7 mmol/L [126 mg/dL] or a clinical diagnosis of type 2 diabetes with ongoing antidiabetic treatment) (20). In a sensitivity analysis, the most recent diagnostic criteria were applied (fasting glucose ≥7 mmol/L [126 mg/dL] or a clinical diagnosis of type 2 diabetes with ongoing antidiabetic treatment or HbA1c levels ≥6.5% or 2-h glucose level ≥11.1 mmol/L [200 mg/dL] after a standard 75-g glucose load) (21). The BMI was calculated as weight divided by height squared (kg/m²). Smoking status and alcohol consumption were recorded as detailed previously (15–17). Physical activity was recorded by composed score for work (three categories) and sports/leisure activities (0, ≤2, and >2 h per week) (15–17). Socioeconomic status was categorized on a three-category scale (low, medium, and high) based on information about occupational status and educational level of the person with the highest income in the household (15–17). Blood samples were drawn after an overnight fast and abstinence from smoking. Total cholesterol, HDL cholesterol, uric acid, creatinine, ferritin, and high-sensitivity C-reactive protein were all assessed by standard methods (15–17). LDL cholesterol was calculated with the Friedewald formula except for patients with a triglyceride level >400 mg/dL. Vascular cellular adhesion molecule (VCAM)-1 was detected by enzyme-linked immunosorben assay (17).

Longitudinal assessment of arthroplasty between 1990 and 2010
Localization, date, and circumstances of total hip and knee arthroplasty occurring between 1990 and 2010 were carefully recorded using three sources of information: subject self-report, medical records of the Bruneck Hospital and general practitioners, and a standardized evaluation of all radiographs ever taken on study subjects. Arthroplasty following bone fractures (documented by radiographs) was not considered in the current analysis. All subjects with arthroplasty had radiographically documented OA of the hip or knee joint in at least two sequential radiographs (Kellgren-Lawrence score of at least one) before surgery and met the criteria for the diagnosis of OA (22,23). Two independent readers (R.L. and C.P.) unaware of the status of diabetes assessed the radiographs.

Cross-sectional clinical assessment of OA in 2010
In the 2010 follow-up exam, a total of 576 individuals were still alive and had full information on arthroplasty and of these, 488 participated in fourth follow-up. The self-administered questionnaires of the Knee Injury and Osteoarthritis Outcome Score (KOOS) and the Western Ontario and McMaster University Osteoarthritis Index (WOMAC), both addressing the severity of symptoms (pain, stiffness, and joint function) associated with OA, were filled out by 347 men and women who did not differ from the overall group of 488 participants in any of the population characteristics assessed.

Cross-sectional imaging assessment of OA in 2010
In order to evaluate the severity of knee OA, bilateral ultrasound (US) examination of the knee joints was performed by an independent experienced examiner blinded to clinical symptoms and presence of laboratory or radiographic abnormalities in 443 individuals (90.8%) (24–26). The US exam was performed by a single reader (C.P.) using an ESAOTE MyLab25 US system (Esaeote Biomedica, Genoa, Italy) equipped with a broadband 4–13 MHz linear transducer for US examination. Both transverse and longitudinal scans of the supra- and infrapatellar region and the lateral and medial recesses were performed. Presence of synovitis (i.e., hypoechoic synovial hypertrophy and joint effusion according to the Outcome Measures in Rheumatology definition) in grayscale and power Doppler signal in the synovial membrane (settings: pulse repetition frequency 750 Hz, gain 40–50 dB) were recorded in each compartment. Presence of grayscale synovial hypertrophy and joint effusion as well as Doppler signal was recorded according to a semiquantitative scale (0 = normal; 1 = mild change; 2 = moderate change; 3 = severe change). The summed total score of inflammatory-related abnormalities (effusion, synovial hypertrophy, and power Doppler signal) was also calculated (range from 0–9 in each joint).

Statistical analysis
Data were analyzed using the statistical packages SPSS version 18.0 (SPSS) and STATA version 10.1 (StataCorp). For computation of intervention rates, person-years
of follow-up for each participant were accrued from the 1990 baseline until arthroplasty, age 90 years, death, or 1 October 2010, whichever came first. Cox proportional hazard models were fitted to assess the association between baseline type 2 diabetes and arthroplasty due to severe OA during follow-up. The proportional hazard assumption was confirmed for type 2 diabetes by testing the interaction of type 2 diabetes with a function of survival time (Cox model with time-dependent covariates). When the exact date of arthroplasty was not available, we used the date of the first X-ray showing the implant as a surrogate. This may be viewed as an adequate approximation in most individuals and, if at all, err on the conservative side. The base model was unadjusted, whereas multivariable models were adjusted for established predictors of severe OA [age, sex, prior arthroplasty, BMI, and log-transformed level of soluble VCAM-1 (17); model 1] and, additionally, for social class, smoking, alcohol consumption, physical activity score, and levels of uric acid, creatinine, LDL cholesterol, log-transformed high-sensitivity C-reactive protein (hsCRP), and ferritin (model 2). Differential effects of type 2 diabetes on the probability of arthroplasty in subgroups according to age, sex, and BMI were tested by inclusion of appropriate interaction terms. Sensitivity analyses with an update of key variable (diabetes status and BMI) were fitted using Cox regression analysis with time-dependent covariates in order to control for switches in diabetes status with time-dependent covariates in order to control for switches in diabetes status. Mean time between diagnosis of type 2 diabetes and manifestation of severe OA. Mean time between diagnosis of type 2 diabetes and joint failure necessitating surgical intervention was 10.7 years in our cohort. In line, type 2 diabetes disease duration was

RESULTS

Prospective analysis of arthroplasty in subjects with and without type 2 diabetes in the Bruneck Study (1990–2010)

At baseline, 69 of the 927 participants of the Bruneck Study met the diagnostic criteria for type 2 diabetes. Mean HbA1c at baseline was 7.2%. Oral antidiabetic drugs were used in 41 and insulin in 3 of the 69 participants. A total of 31 of the 69 patients with diabetes (44.9%) had clinical signs of a polyneuropathy at baseline (mild, 20; moderate, 11; severe, 0), and this proportion increased to 55.1% during follow-up (mild, 22; moderate, 16; severe, 0). No subjects had been affected by type 1 diabetes. Baseline characteristics of diabetic and nondiabetic subjects are summarized in Table 1.

Between 1990 and 2010, 16 arthroplasties due to severe symptomatic hip/knee OA were performed in diabetic subjects corresponding to an intervention rate (95% CI) of 17.7 (9.4–30.2) per 1,000 person-years. During the same period, 73 interventions were done in the nondiabetic group corresponding to an intervention rate (95% CI) of 5.3 (4.1–6.6) per 1,000 person-years. In unadjusted Cox models, the hazard ratio (HR) [95% CI] of joint failure for type 2 diabetes was 3.8 (2.1–6.8) (P < 0.001) (Table 2). Remarkably, type 2 diabetes remained a significant predictor of arthroplasty after controlling for a variety of other putative risk factors for OA including age and BMI (HR [95% CI], 2.1 [1.1–3.8]; P = 0.023). To account for weight gain during follow-up (e.g., related to insulin treatment), BMI was updated every 5 years during follow-up from 1990–2010 (Table 2). This sensitivity analysis yielded similar risk estimates for type 2 diabetes (HR [95% CI], 2.2 [1.2–4.1]; P = 0.013). Several further sensitivity analyses with an update of diabetes status during follow-up or application of the most recent American Diabetes association definition of diabetes (21) yielded very similar results (Table 2). Findings were also consistent when additionally adjusting the analysis for lifestyle factors including smoking and physical activity and serum parameters such as CRP (HR [95% CI], 2.1 [1.1–4.0]; P = 0.026) (Table 2). Moreover, results were similar in men and women and subgroups according age and BMI (P values for interaction: 0.421, 0.844, and 0.192). Of note, severity of OA, as assessed by the Kellgren-Lawrence score (range 0–10 points) in the last radiograph prior to arthroplasty, was similar in subjects with and without type 2 diabetes (mean ± SD: 5.5 ± 1.7 vs. 5.8 ± 1.6 points, both values resembling severe radiographic Kellgren-Lawrence stage 3 OA; P = 0.84), as was the mean age at surgery (74.1 vs. 72.6 years; P = 0.35).

In the cumulative hazard plot (Fig. 1), the lines for diabetic and nondiabetic subjects diverged over time, indicating relevance of disease duration for the manifestation of severe OA. Mean time between diagnosis of type 2 diabetes and joint failure necessitating surgical intervention was 10.7 years in our cohort. In line, type 2 diabetes disease duration was

| Characteristic* | No (n = 858) | Yes (n = 69) | P value† |
|----------------|------------|------------|---------|
| Age (years)    | 58.2 ± 11.3| 67.6 ± 9.6 | <0.001  |
| Male sex (%)   | 50.3       | 49.7       | 0.451   |
| BMI (kg/m²)    | 24.8 ± 3.7 | 27.0 ± 3.9 | <0.001  |
| Social status (%) |         |           |         |
| Low            | 61.4       | 75.4       | 0.923   |
| Medium         | 21.7       | 7.2        |         |
| High           | 16.93      | 17.4       |         |
| sVCAM-1 (ng/mL)| 609.2 (491.8–789.7) | 736.9 (600.9–876.7) | 0.036   |
| Smoking (%)    | 24.7       | 18.8       | 0.636   |
| Alcohol consumption (g/day) | 30.8 ± 40.6 | 36.56 ± 49.0 | 0.385  |
| Physical activity (score) | 4.4 ± 1.5  | 3.6 ± 1.6  | 0.011   |
| Uric acid (µmol/L) | 315.2 ± 83.3 | 368.8 ± 113.0 | 0.005  |
| Creatinine (µmol/L) | 69.8 ± 36.2 | 71.4 ± 15.0 | 0.853   |
| LDL cholesterol (mmol/L) | 3.56 ± 0.98 | 3.78 ± 1.09 | 0.147   |
| hsCRP (mg/L)   | 1.4 (0.8–5.7) | 3.1 (1.4–8.0) | 0.001   |
| Ferritin (pmol/L) | 318.8 ± 340.6 | 613.4 ± 783.5 | <0.001  |

sVCAM-1, soluble VCAM-1. *Values presented are means ± SD, median (interquartile range), or percentages. Factors to convert Système International units into conventional units are as follows: LDL cholesterol, 0.02586; and creatinine, 88.4. †P values for the variables age and sex are from unadjusted analyses. All other P values are from logistic regression models adjusted for age and sex. For computation of P values, CRP and sVCAM levels were log-transformed because of a markedly skewed distribution.
Diabetes and osteoarthritis

Table 2—Prospective association of type 2 diabetes with severe OA requiring joint arthroplasty during 20 years of follow-up (Bruneck Study 1990–2010, n = 927)

| Arthroplasty | Participants without type 2 diabetes (n = 858) | Participants with type 2 diabetes (n = 69) | P value |
|-------------|---------------------------------------------|--------------------------------------|--------|
| No. of cases | 73                                          | 13                                   |        |
| Person-years of follow-up | 13,835                        | 735                                  |        |
| Intervention rate per 1,000 person-years | 5.3 (4.1–6.6) | 17.7 (9.4–30.2) |        |

HR and 95% CI were derived from Cox regression analysis. Participants with arthroplasty and those turning 90 years of age were censored for subsequent follow-up. aAdjusted for age, sex, prior joint replacement, BMI, and log-transformed level of soluble VCAM-1. In this analysis, baseline BMI was updated every 5 years (Cox regression analysis with time-dependent covariate) to account for weight gain (e.g., related to insulin treatment). bIn this analysis, baseline diabetes status was continuously updated during the 20-year follow-up period (Cox regression analysis with time-dependent covariate). cIn this analysis, baseline diabetes status was continuously updated during the first 10-year follow-up period (Cox regression analysis with time-dependent covariate). dIn this analysis, baseline diabetes status was continuously updated during the first 10-year follow-up period (Cox regression analysis with time-dependent covariate). eIn this analysis, baseline diabetes status was continuously updated during the first 10-year follow-up period (Cox regression analysis with time-dependent covariate). fUnadjusted 1 (Reference) 3.76 (2.07–6.81) <0.001. gSix subjects with arthroplasty due to severe OA (unadjusted HR [95% CI], 3.95; P = 0.025).

CONCLUSIONS—To our best knowledge, this is the first time that it was shown that diabetes can be considered as an independent predictor of severe OA necessitating joint arthroplasty. OA is a major challenge to health in the industrialized world. 1) Its prevalence is high and further increases due to ageing of the populations. 2) Furthermore, its impact on quality of life is substantial due to an impairment of locomotor function and decrease in functional capacities. 3) Finally, its conservative treatment options are limited, and surgical replacement of damaged joints may be necessary in severe cases. Therefore, definition of risk predictors for OA is of key importance, particularly if these risk factors can be modified by either lifestyle changes or medications.

In this study, we show that long-standing type 2 diabetes is independently associated with advanced OA of knee and hip joints. This finding adds to the yet short list of risk predictors for OA established in prospective evaluations (5,6,17). After controlling the analysis for age, BMI, and other potential confounders, type 2 diabetes comprised a twofold risk of severe OA necessitating arthroplasty.

The population-based design is a strength of this study (27,28), as well as its long-term and complete follow-up and the use of joint failure necessitating arthroplasty as a hard end point. A further strength of our study is that the link between type 2 diabetes and OA was consistent when using three distinct approaches of OA ascertainment as follows: 1) joint failure as determined by arthroplasty; 2) signs and symptoms of OA as quantified by the WOMAC and KOOS scores; and 3) severity of joint changes as determined by musculoskeletal US.

The moderate number of arthroplasties (<100) can be considered as a limitation of study. However, this is not surprising because arthroplasty accomplishes the most significantly higher in diabetic patients with arthroplasty than in those without arthroplasty (Fig. 1).

Subjects with impaired fasting glucose at baseline (1990, n = 86) showed a moderately elevated risk of arthroplasty due to severe OA (unadjusted HR [95% CI], 2.0 [1.1–3.7]; P = 0.030), which lost significance in the multivariable model (HR [95% CI], 1.6 [0.9–3.0]; P = 0.145).

Cross-sectional analysis of OA in diabetic and nondiabetic subjects in 2010

On a cross-section (2010), patients with prevalent diabetes (n = 74) were more likely to have received replacement of knee and hip joint (implanted for alleviation of OA symptoms) than nondiabetic individuals (knee arthroplasty, intervention proportion 10.8 vs. 3.3%, P = 0.006; hip arthroplasty, intervention proportion 9.5 vs. 5.0%, P = 0.167). To further elaborate the association between type 2 diabetes and OA, a number of ancillary cross-sectional analyses were performed. Evaluation of the clinical symptoms of OA by total WOMAC score, a validated patient-related measure of signs and symptoms of OA, showed significantly more severe OA symptoms in subjects with type 2 diabetes than in controls (Table 3). Results were consistent in unadjusted (P = 0.034) and fully adjusted models (P = 0.030). Moreover, WOMAC subscales for joint pain and function were lower (i.e., more pathologic in type 2 diabetic patients than controls) (P values from multivariable analyses 0.014 and 0.004; Table 3). Finally, results were replicated when applying another validated score for the quantification of clinical disease activity in OA, the KOOS questionnaire (pain score, P value from multivariable analyses 0.001; Table 3).

We performed examinations of knee joints by US in 443 individuals of the Bruneck Study population in 2010 (90.8%), searching for signs of inflammation including synovitis and joint effusion. Subjects without US data (n = 55) were more likely to be female and diabetic but otherwise similar to the entire population. Bilateral joint effusion was found in 51.1% of subjects with type 2 diabetes but only in 30.9% of the subjects without type 2 diabetes (Table 3). In accordance, uni- and bilateral signs of synovitis in the knee joints were significantly more frequent in diabetic than nondiabetic subjects (P value from multivariable analyses 0.004; Table 3). Data were consistent when focusing on both synovitis and effusion in a single model (P value from multivariable analyses 0.003; Table 3). Finally, severity of synovitis as quantified by the synovitis score was more pronounced among patients with type 2 diabetes (Table 2).
severe disease phenotype of OA, which is less prevalent. Moreover, results from our study launched in a small town, in which accessibility to health resources is very high, are not necessarily representative for other Western populations and await confirmation in independent studies. Also, we cannot exclude different decision-making for arthroplasty in diabetic versus nondiabetic subjects. Subjects with diabetes may receive more medical attention than nondiabetic individuals, leading to increased awareness of or even overtreatment of OA. Moreover, fear of deterioration of the general medical condition in diabetic subjects could, at least theoretically, lead to earlier interventions in this group. In contrast, studies showing a higher risk of complications and of revisions of arthroplasty in diabetic subjects could, at least theoretically, lead to earlier interventions in this group. In contrast, studies showing a higher risk of complications and of revisions of arthroplasty in diabetic subjects could translate into a more conservative indication for surgical interventions resulting in an underestimation rather than overestimation of the effect size of diabetes in our study (29). Actually, in the current study, radiographic severity of OA prior to surgery (Kellgren-Lawrence score) and the age at arthroplasty both were identical in subjects with and without type 2 diabetes, suggesting no major differences in the indication for interventions in these groups.

The link between obesity and OA is well-established and particularly supported by longitudinal data showing that obesity entails a higher risk for developing severe OA (6). Traditionally, mechanical factors have been considered to explain more rapid joint degeneration in obese individuals. However, this concept has been challenged by the link between obesity and OA in non-weight-bearing joints, suggesting that metabolic changes directly enhance the risk of OA. Despite evidence from cross-sectional studies that OA is linked to the metabolic syndrome and higher blood glucose levels (10–12), no study addressed whether diabetes is independently linked to OA and in particular whether such a link is independent of body weight. Our study is the first to show that type 2 diabetes predicts severe OA independent of age, sex, and BMI and provides both longitudinal and cross-sectional evidence for an independent association between type 2 diabetes and OA.

Moreover, several lines of experimental evidence may help to explain the link between type 2 diabetes and OA: 1) chondrocytes express the GLUT/SLC2A, and high blood glucose levels shift the synthesis pattern of chondrocytes from type II collagen to reactive oxygen species, potentially mediating cartilage destruction (30–32). 2) Advanced glycosylation end products elicited by sustained hyperglycemia can stimulate chondrocyte expression of proinflammatory and prodegenerative proteins via the receptor for advanced glycosylation end products (33–35). In this context, it is worth mentioning that elevated circulating levels of interleukin-6 and tumor necrosis factor-α have recently been demonstrated in patients with knee OA (36). Moreover, our data from knee US showed that signs of inflammation are more frequent and severe in the joints of diabetic subjects than nondiabetic individuals. 3) Finally, sensory and motor polyneuropathy is a common complication of type 2 diabetes and may increase the risk of OA by muscle weakness and loss of vibratory sense (37) with subsequent inappropriate use of the affected joint due to altered mechanical stress forces. In this context, it is noteworthy that the pain subscales of the WOMAC and KOOS scores exhibit particularly pronounced associations with type 2 diabetes (Table 2). Sensory polyneuropathy obviously does not offset the high burden of pain in OA among diabetic subjects, rendering this potential link even more robust.

Our study fosters the concept that OA is part of the metabolic syndrome. This
Diabetes and osteoarthritis

Table 3—Cross-sectional association of type 2 diabetes with clinical scores (WOMAC Osteoarthritis Index and KOOS) and US measures of knee OA (Bruneck Study 2010)

|                         | Participants without type 2 diabetes (n = 304) | Participants with type 2 diabetes (n = 43) | P valuea | P valueb |
|-------------------------|-----------------------------------------------|------------------------------------------|----------|----------|
| WOMAC and KOOS (n = 347)c [median (IQR)] |                                |                                          |          |          |
| KOOS Pain Score         | 97.2 (88.9–100)                              | 91.7 (69.4–100)                          | 0.001    | 0.001    |
| KOOS Symptoms Score     | 96.4 (85.7–100)                              | 89.3 (78.6–100)                          | 0.211    | 0.160    |
| WOMAC Pain              | 100 (90.0–100)                               | 95.0 (77.5–100)                          | 0.011    | 0.014    |
| WOMAC Stiffness         | 100 (75.0–100)                               | 100 (62.5–100)                           | 0.495    | 0.603    |
| WOMAC Functiond         | 98.5 (90.9–100)                              | 94.1 (79.4–100)                          | 0.005    | 0.004    |
| WOMAC Total Score       | 97.8 (89.6–100)                              | 93.8 (79.2–100)                          | 0.034    | 0.030    |

Joint ultrasonography (n = 438)c

|                         | Participants without type 2 diabetes (n = 391) | Participants with type 2 diabetes (n = 47) |
|-------------------------|-----------------------------------------------|------------------------------------------|
| Effusion                |                                              |                                          |          |          |
| No [n (%)]              | 138 (35.3)                                    | 7 (14.9)                                 | 0.001    | 0.007    |
| Unilateral [n (%)]      | 132 (33.8)                                    | 16 (34.0)                                |          |          |
| Bilateral [n (%)]       | 121 (30.9)                                    | 24 (51.1)                                |          |          |
| Synovitis               |                                              |                                          |          |          |
| No [n (%)]              | 209 (53.5)                                    | 13 (27.7)                                |          |          |
| Unilateral [n (%)]      | 112 (28.6)                                    | 17 (36.2)                                |          |          |
| Bilateral [n (%)]       | 70 (17.9)                                     | 17 (36.2)                                |          |          |
| Effusion and synovitis  |                                              |                                          |          |          |
| Neither criterion [n (%)] | 133 (34.0)                                   | 6 (12.8)                                 |          |          |
| All other [n (%)]       | 193 (49.4)                                    | 25 (53.2)                                |          |          |
| Both criteria in both knees [n (%)] | 65 (16.6)                               | 16 (34.0)                                |          |          |

A total of 488 individuals participated in the 2010 follow-up exam, and a random subsample of 347 completed the KOOS questionnaire including the WOMAC Osteoarthritis Index. Specific subscores were calculated as follows: KOOS Activities of Daily Living Score, Pain Score, and Other Symptoms Score; WOMAC Pain Score, Stiffness Score, and Function Score. All scores were transformed to a scale of 0–100, with higher values indicating better function and fewer symptoms, respectively. Knee US was performed in a representative subsample of 443 individuals and focused on effusion and synovitis. A US synovitis score was calculated and had a range of 0–20. Five subjects with rheumatoid or psoriatic arthritis of the knee joints were excluded, leaving 438 for the current analysis. Values from adjusted analyses (general linear models and logistic regression analysis). Adjustment was performed for age, sex, BMI, social class, smoking, alcohol consumption, physical activity score, and levels of uric acid, creatinine, LDL cholesterol, log-transformed hsCRP, and ferritin. Clinical scores were log-transformed for computation to approximate a normal distribution. Effusion and synovitis was coded present in case of previous arthroplasty due to severe OA. Supplementary analyses that exclude subjects with previous total knee replacement yielded virtually identical results. The target variable effusion and synovitis differentiates three categories: 1) neither effusion nor synovitis in both knees; 2) both effusion and synovitis in both knees; and 3) all other. The WOMAC Function Score is identical to the KOOS Activities of Daily Living Score.

Table 3—Cross-sectional association of type 2 diabetes with clinical scores (WOMAC Osteoarthritis Index and KOOS) and US measures of knee OA (Bruneck Study 2010)

No potential conflicts of interest relevant to this article were reported.

G.S. wrote the manuscript, researched data, contributed to discussion, and reviewed and edited the manuscript. A.K., C.P., E.S., J.Z., R.L., and F.A. researched data. A.I. reviewed and edited the manuscript. F.B., M.-A.D., and J.W. contributed to discussion. S.K. re-searched data, contributed to discussion, and reviewed and edited the manuscript. G.S. and S.K. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

References

1. Felson DT. Epidemiology of osteoarthritis. In Osteoarthritis. Brandt KD, Doherty M, Lohmander LS, Eds. Oxford, Oxford University Press, 2003
2. Nüesch E, Dieppe P, Reichenbach S, Williams S, Illi S, Jüni P. All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. BMJ 2011;342:d1165
3. NIH Consensus Development Panel on Total Hip Replacement. NIH consensus conference: Total hip replacement. JAMA 1995;273:1930–1956
4. Agency for Healthcare Research and Quality. Hospital-based care in the United States Healthcare Cost and Utilization Project (HCUP): Facts and Figures 2006. Available at http://www.hcup-us.ahrq.gov/reports/factsandfigures2009/exhibit5_4.jsp. Accessed 7 Aug 2012
5. Hawker GA, Guan J, Croxford R, et al. A prospective population-based study of the predictors of undergoing total joint arthroplasty. Arthritis Rheum 2006;54:3212–3220
6. Felson DT, Anderson JJ, Naimark A, Walker AM, Meenan RF. Obesity and knee osteoarthritis. The Framingham Study. Ann Intern Med 1988;109:18–24
7. Apold H, Meyer HE, Espehaug B, Nordsetten L, Havelin LI, Flugsrud GB. Weight gain and the risk of total hip replacement a population-based prospective cohort study of 265,723 individuals. Osteoarthritis Cartilage 2011;19:800–815
8. Berenbaum F. Diabetes-induced osteoarthritis: from a new paradigm to a new phenotype. Ann Rheum Dis 2011;70:1354–1356
9. Pottie P, Presle N, Terlain B,Netter P, Mainard D, Berenbaum F. Obesity and osteoarthritis: more complex than predicted! Ann Rheum Dis 2006;65:1403–1405
10. Puenpatom RA, Victor TW. Increased prevalence of metabolic syndrome in individuals with osteoarthritis: an analysis of NHANES III data. Postgrad Med 2009;121:9–20
11. Cimmino MA, Cutolo M. Plasma glucose concentration in symptomatic osteoarthritis: a clinical and epidemiological survey. Clin Exp Rheumatol 1990;8:251–257
12. Hart DJ, Doyle DV, Spector TD. Association between metabolic factors and knee osteoarthritis in women: the Chingford Study. J Rheumatol 1995;22:1118–1123
13. Waine H, Nevinny D, Rosenthal J, Joffe IB. Association of osteoarthritis and diabetes mellitus. Tufts Folia Med 1961;7:13–19
14. Stürmer T, Brenner H, Brenner RE, Günther KP. Non-insulin dependent diabetes mellitus (NIDDM) and patterns of osteoarthritis. The Ulm osteoarthritis study. Scand J Rheumatol 2001;30:169–171
15. Kiechl S, Lorenz E, Reindl M, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002;347:185–192
16. Schett G, Kiechl S, Redlich K, et al. Soluble RANKL and risk of nontraumatic fracture. JAMA 2004;291:1108–1113
17. Schett G, Kiechl S, Bonora E, et al. Vascular cell adhesion molecule 1 as a predictor of severe osteoarthritis of the hip and knee joints. Arthritis Rheum 2009;60:2381–2389
18. Seshasai SR, Kaptoge S, Thompson A, et al.; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011;364:829–841
19. Bonora E, Kiechl S, Mayr A, et al. High-normal HbA1c is a strong predictor of type 2 diabetes in the general population. Diabetes Care 2011;34:1038–1040
20. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997;20:1183–1197
21. American Diabetes Association. Standards of medical care in diabetes—2010. Diabetes Care 2010;33(Suppl. 1):S11–S61
22. Altman R, Asch E, Bloch D, et al.; Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Arthritis Rheum 1986;29:1039–1049
23. Altman R, Alarcón G, Appelrouth D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 1991;34:505–514
24. D’Agostino MA, Conaghan P, Le Bars M, et al. EULAR report on the use of ultrasonography in painful knee osteoarthritis. Part 1: prevalence of inflammation in osteoarthritis. Ann Rheum Dis 2005;64:1703–1709
25. Conaghan P, D’Agostino MA, Ravaud P, et al. EULAR report on the use of ultrasonography in painful knee osteoarthritis. Part 2: exploring decision rules for clinical utility. Ann Rheum Dis 2005;64:1710–1714
26. Conaghan PG, D’Agostino MA, Le Bars M, et al. Clinical and ultrasonographic predictors of joint replacement for knee osteoarthritis: results from a large, 3-year, prospective EULAR study. Ann Rheum Dis 2010;69:644–647
27. Frankel S, Eachus J, Pearson N, et al. Population requirement for primary hip-replacement surgery: a cross-sectional study. Lancet 1999;353:1304–1309
28. Jüni P, Dieppe P, Donovan J, et al. Population requirement for primary knee replacement surgery: a cross-sectional study. Rheumatology (Oxford) 2003;42:516–521
29. Pedersen AB, Mehnert F, Johnsen SP, Sørensen HT. Risk of revision of a total hip replacement in patients with diabetes mellitus: a population-based follow up study. J Bone Joint Surg Br 2010;92:929–934
30. Shihman AR, Brinson DC, Valbracht J, Lotz MK. Cytokine regulation of facilitated glucose transport in human articular chondrocytes. J Immunol 2001;167:7001–7008
31. Roza SC, Gonçalves J, Judas F, Mobasher A, Lopes C, Mendes AF. Impaired glucose transporter-1 degradation and increased glucose transport and oxidative stress in response to high glucose in chondrocytes from osteoarthritic versus normal human cartilage. Arthritis Res Ther 2009;11:R80
32. Hemtotin YE, Bruckner P, Pujol JP. The role of reactive oxygen species in homeostasis and degradation of cartilage. Osteoarthritis Cartilage 2003;11:747–755
33. Steenvoorde MM, Huizinga TW, Verzijl N, et al. Activation of receptor for advanced glycation end products in osteoarthritis leads to increased stimulation of chondrocytes and synoviocytes. Arthritis Rheum 2006;54:253–263
34. Loeser RF, Yammani RR, Carlson CS, et al. Articular chondrocytes express the receptor for advanced glycation end products: Potential role in osteoarthritis. Arthritis Rheum 2005;52:2376–2385
35. Verzijl N, DeGroot J, Ben ZC, et al. Crosslinking by advanced glycation end products increases the stiffness of the collagen network in human articular cartilage: a possible mechanism through which age is a risk factor for osteoarthritis. Arthritis Rheum 2002;46:1113–1123
36. Stammus O, Jones G, Ciccinti F, et al. Circulating levels of IL-6 and TNF-α are associated with knee radiographic osteoarthritis and knee cartilage loss in older adults. Osteoarthritis Cartilage 2010;18:1441–1447
37. Slemenda C, Brandt KD, Heilman DK, et al. Quadriceps weakness and osteoarthritis of the knee. Ann Intern Med 1997;127:97–104